Toxicity and dose determination of quillaja saponin, aluminum hydroxide and squalene in olive flounder (Paralichthys olivaceus)

Veterinary Immunology and Immunopathology

Volumn 158, Issue 1-2, 2014, Pages 73-85

  Vinay, Tharabenahalli Nagaraju ^a   Park, Chang Su ^a   Kim, Heung Yun ^a   Jung, Sung Ju ^a  

^a Chonnam National University   (South Korea)

Author keywords

Adjuvant; Aluminum hydroxide; Dose; Olive flounder; Saponin; Squalene; Toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ALUMINUM HYDROXIDE; ASPARTATE AMINOTRANSFERASE; FREUND ADJUVANT; QUILLAJA SAPONIN; SQUALENE;

ACUTE TOXICITY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; EMULSION; FINGERLING; HISTOPATHOLOGY; INJECTION SITE INFLAMMATION; LD 50; LIVER HISTOLOGY; LIVER INJURY; NONHUMAN; PARALICHTHYS OLIVACEUS; VACCINATION;

PARALICHTHYS OLIVACEUS; QUILLAJA;

ADJUVANT; ALUMINUM HYDROXIDE; DOSE; OLIVE FLOUNDER; SAPONIN; SQUALENE; TOXICITY;

ADJUVANTS, IMMUNOLOGIC; ALANINE TRANSAMINASE; ALUMINUM HYDROXIDE; ANIMALS; ASPARTATE AMINOTRANSFERASES; FLOUNDER; FREUND'S ADJUVANT; HISTOCYTOCHEMISTRY; LETHAL DOSE 50; LIPIDS; QUILLAJA SAPONINS; RANDOM ALLOCATION; SQUALENE; VACCINATION;

EID: 84896696320     PISSN: 01652427     EISSN: 18732534     Source Type: Journal    
DOI: 10.1016/j.vetimm.2013.03.007     Document Type: Article

References (47)

1. Alving C.R. Design and selection of vaccine adjuvants: animal models and human trials. Vaccine 2002, 20:56-64.
2. Aucouturier J., Dupuis L., Ganne V. Adjuvants designed for veterinary and human vaccines. Vaccine 2001, 19:2666-2672.
3. Batista D., Lindblad A., Oviedo-Orta E.B.E. Progress in understanding adjuvant immunotoxicity mechanisms. Toxicol. Lett. 2011, 203:97-105.
4. Bowden T.J., Adamson K., Maclachlan P., Pert C.C., Bricnell I.R. Long-term study of antibody response and injection-site effects of oil adjuvants in Atlantic halibut (Hippoglossus hippoglossus L.). Fish Shellfish Immunol. 2003, 14:363-369.
5. Chawla R. Practical Clinical Biochemistry Methods and Interpretations 1999, 107-134. Jaypee. 2nd ed.
6. Committee for medicinal products for human use (CPMP), 2004. Guideline on adjuvants in vaccines for human use. EMEA/CHMP/VEG/134716/2004.
7. Corradin G., Giudice G.D. Novel adjuvants for vaccines. Curr. Med. Chem. Anti-Inflamm. Anti-Allergy Agents 2005, 4.
8. Dalsgard K. A study of the isolation and characterization of the saponin Quil A. Evaluation of its adjuvant activity, with a special reference to the application in the vaccination of cattle foot-and-mouth disease. Acta Vet. Scand. 1978, (Suppl. 69):7-40.
9. Drangsholt T.M.K., Gjerde B., Ødegård J., Fridell F., Bentsen H.B. Quantitative genetics of vaccine-induced side effects in farmed Atlantic Salmon (Salmo salar). Aquaculture 2011, 318:316-324.
10. Evensen, Ø., 2009. Development in fish vaccinology with focus on delivery methodologies, adjuvants and formulations. The use of veterinary drugs and vaccines in Mediterranean aquaculture. A/no. 86.
11. Evensen Ø., Brudeseth B., Mutoloki The vaccine formulation and its role in inflammatory processes in fish - effects and adverse effects. Dev. Biol. 2005, 121:117-125.
12. Fox C.B. Squalene emulsions for parenteral vaccine and drug delivery. Molecules 2009, 14:3286-3312.
13. Giudice G.D., Podda B.A., Rappuoli R. What are the limits of adjuvantacity?. Vaccine 2002, 20:S38-S41.
14. Gjessing M.C., Falk K., Weli S.C., Koppang E.O., Kvellestad A. A sequential study of incomplete Freund's adjuvant-induced peritonitis in Atlantic cod. Fish Shellfish Immunol. 2012, 32:141-150.
15. Gregorio E.D., Tritto E., Rappuoli R. Alum adjuvantacity: unraveling a century old mystery. Eur. J. Immunol. 2008, 38:2068-2071.
16. Gudding R., Lillehaug A., Midtlyng P.J., Brown F. Fish Vaccinology 90 1997, 371-379. Dev Biol Stand, Basel, Karger.
17. Gudding R., Lillehaug A., Evensen Recent developments in fish vaccinology. Vet. Immunol. Immunopathol. 1999, 72:203-212.
18. Gupta R.K., Relyveld E.H., Lindblad E.B., Bizzini B., Ben-Efraim S., Gupta C.K. Adjuvants - a balance between toxicity and adjuvantacity. Vaccine 1993, 11:293-306.
19. Horne M.T., Roberts R.J., Tatner M. The effects of the use of potassium alum adjuvant in vaccines against vibriosis in rainbow trout, Salmo gairdneri Richardson. J. Fish. Dis. 1984, 7:91-99.
20. Kensil C.R., Patel U., Lennic M., Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J. Immunol. 1991, 146:431-437.
21. Kim M.S., Kim K.H. Protection of olive flounder, Paralichthys olivaceus, against viral hemorrhagic septicemia virus (VHSV) by immunization with NV gene-knockout recombinant VHSV. Aquaculture 2011, 314:39-43.
22. Koppang E.O., Haugarvoll E., Hordvik I., Aune L., Poppe T.T. Vaccine-associated granulomatous inflammation and melanin accumulation in Atlantic salmon, Salmo salar L., white muscle. J. Fish. Dis. 2005, 28:13-22.
23. Lillehaug A., under L., Poppe T.T.T. Field testing of adjuvanted furunculosis vaccines in Atlantic salmon, Salmo salar L. J. Fish. Dis. 1992, 15:485-496.
24. Marciani D.J. Vaccine adjuvants: role and mechanism of action in vaccine immunogenicity. Drug Discov. Therap. 2003, 8:934-943.
25. Marciani D.J., Pathak A.K., Reynolds R.C., Seitz L., May R.D. Altered immunomodulating and toxicological properties of degraded Quillaja saponaria Molina saponins. Int. Immunopharmacol. 2001, 1:813-818.
26. Midtlyng P.J., Lillehaug A. Growth of Atlantic salmon (Salmo salar) after intraperitoneal administration of vaccines containing adjuvants. Dis. Aquat. Org. 1998, 32:91-97.
27. Midtlyng P.J., Reitan L.J., Lillehaug A., Ramstad A. Protection, immune responses and side effects in Atlantic salmon (Salmo salar L.) vaccinated against furunculosis by different procedures. Fish Shellfish Immunol. 1996, 6:599-613.
28. Mulvey B., Landolt M.L., Busch R.A. Effects of potassium aluminium sulphate (alum) used in an Aeromonas salmonicida bacterin on Atlantic salmon, Salmo salar L. J. Fish. Dis. 1995, 18:495-506.
29. Mutoloki S., Alexandersen S., Evensen Ø. Sequential study of antigen persistence and concomitant inflammatory reactions relative to side-effects and growth of Atlantic salmon (Salmo salar L.) following intraperitoneal injection with oil-adjuvanted vaccines. Fish Shellfish Immunol. 2004, 16:633-644.
30. Novartis Vaccines and Diagnostics, 2007. Data on file.
31. O'Hagan D.T., Ott G.S., De Gregorio E., Seubert A. The mechanism of action of MF59 - an innately attractive adjuvant formulation. Vaccine 2012, 30:4341-4348.
32. Oh M.J., Kim W.S., Kitamura S.I., Lee H.K., Son B.W., Jung T.S., Jung S.J. Change of pathogenicity in Olive flounder Paralichthys olivaceus by co-infection of Vibrio harveyi, Edwardsiella tarda and marine birnavirus. Aquaculture 2006, 257:156-160.
33. Petrovsky N., Aguliar J.C. Vaccine adjuvants: Current state and future trends. Immunol. Cell Biol. 2004, 82:488-496.
34. Poppe T.T., Breck O. Pathology of Atlantic salmon (Salmo salar) intraperitoneally immunized with oil-adjuvanted vaccine. A case report. Dis. Aquat. Org. 1997, 29:219-226.
35. Schultze V., D'Agosto V., Wack A., Novicki D., Zorn J., Hennig R. Safety of MF59™ adjuvant. Vaccine 2008, 26:3209-3222.
36. Secombes C. Will advances in fish immunology change vaccination strategies?. Fish Shellfish Immunol. 2008, 25:409-416.
37. Seikai T. Flounder culture and its challenges in Asia. Rev. Fish. Sci. 2002, 10:421-432.
38. Silveira F., Cibulski S.P., Varela A.P., Marqués J.M., Chabalgoity A., de Costa F., Yendo A.C.A., Gosmann G., Roehe P.M., Fernández C., Ferreira F. Quillaja brasiliensis saponins are less toxic than Quil A and have similar properties when used as an adjuvant for a viral antigen preparation. Vaccine 2011, 29:9177-9182.
39. Summerset I., Krossoy B., Biering E., Frost P. Vaccines for fish in aquaculture. Expert Rev. Vac. 2005, 4(1):89-101.
40. Sun Y., Liu J., Yu H., Gong C. Isolation and evaluation of immunological adjuvant activities of saponins from the roots of Pulsatilla chinensis with less adverse reactions. Int. Immunopharmacol. 2010, 10:584-590.
41. Sun, Hong-Xiang, Yong Xie., Yi-Ping Ye. Advances in saponin -based adjuvants. Vaccine 2009, 27:1787-1796.
42. Vanselow B.A. The application of adjuvants to veterinary medicine. Vet. Bull. 1987, 57:881-896.
43. Witthawaskul P., Panthong A., Kanjanapothi D., Taesothikul T., Lertprasertsuke N. Acute and sub acute toxicities of the saponin mixture isolated from Schefflera leucantha Viguier. J. Ethnopharmacol. 2003, 89(1):115-121.
44. World Health Organization, 1976. Immunological adjuvants. In: Technical Report Ser. no. 595. World Health Organization, Geneva, pp. 3-40.
45. Xiang H.S., Jun P.H., Jiang P.Y. Haemolytic activities and immunologic adjuvant effect of Panax notoginseng saponins. Acta. Pharmacol. Sin. 2003, 24:1150-1154.
46. Xo J., Cheng D., Hu S., Sun Y.H.L. Comparative study of the effects of aluminum adjuvants and Freund's incomplete adjuvant on the immune response to an Edwardsiella tarda major antigen. Vaccine 2010, 28:1832-1837.
47. Xu G., Sheng X., Xing J., Zhan W. Effect of temperature on immune response of Japanese flounder (Paralichthys olivaceus) to inactivated lymphocystis disease virus (LCDV). Fish Shellfish Immunol. 2010, 1-10.